IES20080900A2 - Chemical messenger sensor - Google Patents
Chemical messenger sensorInfo
- Publication number
- IES20080900A2 IES20080900A2 IES20080900A IES20080900A2 IE S20080900 A2 IES20080900 A2 IE S20080900A2 IE S20080900 A IES20080900 A IE S20080900A IE S20080900 A2 IES20080900 A2 IE S20080900A2
- Authority
- IE
- Ireland
- Prior art keywords
- cyclodextrin
- conducting
- anionic
- substrate
- electrode
- Prior art date
Links
- 239000000126 substance Substances 0.000 title abstract description 5
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 125
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 52
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 51
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 43
- 229940076279 serotonin Drugs 0.000 claims abstract description 38
- 239000000758 substrate Substances 0.000 claims abstract description 36
- 239000002322 conducting polymer Substances 0.000 claims abstract description 31
- 229920001940 conductive polymer Polymers 0.000 claims abstract description 31
- -1 cyclodextrin macrocycle Chemical class 0.000 claims abstract description 27
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 25
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 25
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 24
- 229960003638 dopamine Drugs 0.000 claims abstract description 21
- 238000001514 detection method Methods 0.000 claims abstract description 11
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims abstract description 10
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims abstract description 10
- 229930182837 (R)-adrenaline Natural products 0.000 claims abstract description 10
- 229960005139 epinephrine Drugs 0.000 claims abstract description 10
- 229960002748 norepinephrine Drugs 0.000 claims abstract description 10
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002861 polymer material Substances 0.000 claims abstract description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 30
- 125000000129 anionic group Chemical group 0.000 claims description 24
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 17
- 229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000002243 precursor Substances 0.000 claims description 15
- YMMGRPLNZPTZBS-UHFFFAOYSA-N 2,3-dihydrothieno[2,3-b][1,4]dioxine Chemical compound O1CCOC2=C1C=CS2 YMMGRPLNZPTZBS-UHFFFAOYSA-N 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 229920000123 polythiophene Polymers 0.000 claims description 12
- 239000001116 FEMA 4028 Substances 0.000 claims description 10
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 10
- 229960004853 betadex Drugs 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 229920000128 polypyrrole Polymers 0.000 claims description 6
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 4
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 3
- 229940097362 cyclodextrins Drugs 0.000 abstract description 4
- 239000002858 neurotransmitter agent Substances 0.000 abstract description 3
- 230000006461 physiological response Effects 0.000 abstract description 3
- 230000016571 aggressive behavior Effects 0.000 abstract description 2
- 230000036528 appetite Effects 0.000 abstract description 2
- 235000019789 appetite Nutrition 0.000 abstract description 2
- 230000036651 mood Effects 0.000 abstract description 2
- 230000007958 sleep Effects 0.000 abstract description 2
- 239000010408 film Substances 0.000 description 21
- 239000010931 gold Substances 0.000 description 16
- 229910052737 gold Inorganic materials 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 10
- 230000004044 response Effects 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229910003460 diamond Inorganic materials 0.000 description 6
- 239000010432 diamond Substances 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 5
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 4
- 229910021397 glassy carbon Inorganic materials 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 241000894007 species Species 0.000 description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 239000004020 conductor Substances 0.000 description 3
- 238000002484 cyclic voltammetry Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229910002804 graphite Inorganic materials 0.000 description 3
- 239000010439 graphite Substances 0.000 description 3
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 description 3
- 229910052741 iridium Inorganic materials 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229910052762 osmium Inorganic materials 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229910052702 rhenium Inorganic materials 0.000 description 3
- 229910052703 rhodium Inorganic materials 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000010944 silver (metal) Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- GKWLILHTTGWKLQ-UHFFFAOYSA-N 2,3-dihydrothieno[3,4-b][1,4]dioxine Chemical compound O1CCOC2=CSC=C21 GKWLILHTTGWKLQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000005184 irreversible process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
A sensor for the detection of chemical messengers is described herein. In particular, a sensor for the detection of serotonin is reported. Serotonin plays a pivotal role as a neurotransmitter in the modulation of a myriad of physiological responses including anger, aggression, mood, sleep, sexuality, and appetite. An electrode for detecting serotonin comprising a conducting or semiconducting substrate, and a polymer material on said substrate is disclosed. Said polymet conprises a conducting polymer doped with a cyclodextrin macrocycle. Suitable cyclodextrin macrocycles include anionic cyclodextrin macrocycles, for example sulfonated B-cyclodextrins (CDs). Also disclosed is a sensor capable of selectively detecting serotonin in the presence of ascorbic acid, epinephrine, norepinephrine and dopamine.
Description
Title
Chemical Messenger Sensor
Field of the Invention [0001] A sensor for the detection of chemical messengers is described herein In particular, a sensor for the detection of serotonin is reported. Methods of constructing sensors according to the present invention are also described, Suitable materials for the construction of such sensors are disclosed with a view to developing a sensor capable of real-time in-vivo serotonin monitoring.
Background to the Invention [0002] Within the central nervous system a number of chemical messengers serve to maintain and regulate healthy brain function. Amongst these, serotonin (1) plays a pivotal role as a neurotransmitter in the modulation of a myriad of physiological responses including anger, aggression, mood, sleep, sexuality, and appetite.
·* ·*?·..> ·.'- :.'.*«.-rs.»·····
[0003] Implication of serotonin in the regulation of such a wide variety of physiological response has led to its association in a corresponding high number of neurological diseases In particular, imbalances in levels of serotonin in the brain are believed responsible for several psychiatric disorders, including depression. Thus, the ability to reliably monitor serotonin concentrations in-vivo, and on a real time scale would provide further valuable insight into the role of serotonin in the pathophysiology of the aforementioned disorders.
[0004] However, reliable in-vivo monitoring of serotonin is particularly challenging because it co-exists with a number of interfering species capable of oxidising at similar potentials, lnterferant induced false positives ultimately lead to unreliable sensor readings In particular, ascorbic acid (4) represents one of the key target interferants. Other common interferants such as uric acid (5), DOPAC (2) and homovanillic acid (3) are also problematic. The exclusion of these last two species is particularly advantageous as these are metabolites of dopamine, which are known to poison other biosensors reducing their sensitivity As both dopamine and serotonin
v neurotransmitters are active in the brain, there is a need to exclude cross metabolite contamination.
[0005] The English language abstract of Japanese Patent Publication number 9127056 describes a sensor for selectively detecting serotonin in the presence of NO and NO2. The sensor is comprised of three carbon fibre electrodes in a single assembly wherein an operational electrode is moved up and down upon a central axis. The English language abstract of Japanese Patent Publication number 3068858 discloses a simple arrangement forthe electrochemical detection of serotonin. This publication is silent to the detection of serotonin the presence of interferants such as ascorbic acid.
[0006] Notwithstanding the foregoing, it would still be desirable to provide a biosensor capable of reliable real-time in-situ, in-vivo measurement of serotonin in the presence of interfering molecules such as ascorbic acid. Further still, such a biosensor must be able to function in the presence of metabolites without suffering the aforementioned problems associated with metabolite poisoning.
Summary of the Invention [0007] In one aspect, the present invention provides for an electrode for detecting serotonin comprising:
(i) a conducting or semi-conducting substrate; and (ii) a polymer material on said substrate, wherein said polymer comprises a conducting polymer doped with a cyclodextrin macrocycle.
[0008] Desirably, the electrode of the present invention comprises a conducting substrate As will be appreciated by a person skilled in the art the conducting substrate may comprise a metal selected from the group consisting of Pt, Ag, Au, Ru, Rh, Pd,
Re, Os, Ir, Ti, Indium tin oxide (ITO) coated glass and combinations thereof. Further still, the conducting substrate may comprise a non-metallic conductor such as carbon fibres, graphite, glassy carbon, diamond, carbon paste and pyrolithic carbon electrodes, or boron doped diamond. Desirably, the conducting substrate comprises
Au [0009) Preferably, the conducting polymer is a biocompatible conducting polymer. As used herein the term biocompatible is a reference to materials that are non-toxic to biological tissues.
[0010) The conducting polymer of the electrode of the present invention may be selected from the group consisting of polythiophenes, polypyrroles and combinations thereof Desirably, the conducting polymer comprises a polythiophene. Suitably, the conducting polymer comprises PEDOT [polyethylenedioxythiophene] (6) wherein n > 1 .
[0011) Desirably, the cyclodextrin macrocycle comprises an anionic cyclodextrin macrocycle. Further desirably, the anionic cyclodextrin macrocycle comprises an anionic a-cyclodextrin, β-cyclodextrin, y-cyclodextrin and combinations thereof. In a preferred embodiment the anionic cyclodextrin macrocycle comprises an anionic βcyclodextrin.
[0012] It is advantageous that the cyclodextrin macrocycle of the electrode of the present invention is anionic (negatively charged). The negative charge associated with the macrocyclic cage promotes complexation of cationic (positively charged) species within the cage structure. At physiological pH metabolites known to poison prior art electrodes (for example DOPAC and homovanillic acid) are anionic species. As such the electrode construction of the present invenlion should not be affected by these metabolites to the same extent, as the anionic cyclodextrin should repel these anionic metabolites The size of the cavity of the macrocyclic cage, i.e whether α,β, or y, may also function as a size exclusion barrier or the like, allowing complexation of molecules below a certain molecular weight only.
[0013] The electrode works by forming an inclusion complex between the macrocyclic cage immobilised in the polymer and serotonin. The oxidative response of the film to
ΙΕ ο 8 Ο Ϋ Ο ί) serotonin is catalytic. That is, it results in the oxidation of serotonin occurring at a different potential than at the bare electrode (bare = gold, platinum, glassy carbon, etc.) [0014] In a preferred embodiment the anionic cyclodextrin macrocycle comprises a sulfonated cyclodextrin macrocycle. Desirably, the sulfonated cyclodextrin macrocycle may comprise a sulfonated α-cyclodextrin, a sulfonated β-cyclodextrin, a sulfonated ycyclodextrin and combinations thereof. Further preferably, the anionic cyclodextrin macrocycle comprises a sulfonated β-cyclodextrin.
[0015] As used herein the term “sulfonated cyclodextrin macrocycle” refers to any cyclodextrin wherein one or more of the hydroxy groups of the glucopyranoside rings are sulfonated Within the art the term is sometimes used interchangeably with sulfated cyclodextrin. Within this specification the terms sulfated cyclodextrin and sulfonated cyclodextrin are to be interpreted as one in the same provided the definition above is satisfied, i.e. having one or more of the hydroxy groups of the glucopyranoside rings sulfonated. For example, sulfonated β-cyclodextrin (7) is commercially available from Sigma-Alrich® as sulfated β-cyclodextrin.
O
S-ONa or H
II o
[0016] In a further aspect, the invention extends to a method of preparing an electrode for detecting serotonin comprising:
(i) providing a conducting or semi-conducting substrate;
(ii) providing an aqueous solution of monomeric precursor to a conducting polymer and an anionic cyclodextrin;
(iii) contacting said substrate and said aqueous solution; and (iv) applying an electrical potential to provide an anionic cyclodextrin doped conducting polymer film on said substrate.
ΙΕ ο 8 ο s ο ο [0017] Desirably, the monomeric precursor to a conducting polymer comprises a monomeric precursor to a polythiophene, a monomeric precursor to a polypyrrole and combinations thereof. Further desirably, the monomeric precursor to a conducting polymer comprises a monomeric precursor to a polythiophene. Preferably, the monomeric precursor to a conducting polymer comprises ethylenedioxythiophene (EDOT), a precursor to polyethylenedioxythiophene (PEDOT).
(0018] The anionic cyclodextrin is incorporated into the PEDOT during polymerisation as a counter ion in order to neutralise the positive charge formed on the PEDOT chain during the oxidation of the monomer, with one cyclodextrin incorporated for every four EDOT units.
[0019] Desirably, in the method of the present invention the substrate comprises a conducting substrate. As will be appreciated by a person skilled in the art the conducting substrate may comprise a metal selected from the group consisting of Pt, Ag, Au, Ru, Rh, Pd, Re, Os, Ir, Ti, Indium tin oxide (ITO) coated glass and combinations thereof. Further still, the conducting substrate may comprise a nonmetallic conductor such as carbon fibres, graphite, glassy carbon, diamond, carbon paste and pyrolithic carbon electrodes, or boron doped diamond. Desirably, the conducting substrate comprises Au.
[0020] Desirably, the cyclodextrin macrocycle comprises an anionic cyclodextrin macrocycle. Further desirably, the anionic cyclodextrin macrocycle comprises an anionic a-cyclodextrin, β-cyclodextrin, γ-cyclodextrin and combinations thereof. In one embodiment the anionic cyclodextrin macrocycle comprises an anionic β-cyclodextrin [0021] In a preferred embodiment of the method of the present invention the anionic cyclodextrin macrocycle comprises a sulfonated cyclodextrin macrocycle. Desirably, the sulfonated cyclodextrin macrocycle may comprise a sulfonated α-cyclodextrin, a sulfonated β-cyclodextrin, a sulfonated γ-cyclodextrin and combinations thereof Further preferably, the anionic cyclodextrin macrocycle comprises a sulfonated βcyclodextrin.
[0022] The present invention further provides for a sensor for selective detection of serotonin in the presence of dopamine, epinephrine, norepinephrine, ascorbic acid and combinations thereof comprising;
an electrode comprising:
(i) a conducting or semi-conducting substrate; and (ii) a polymer material on said substrate, wherein said polymer comprises a conducting polymer doped with a sulfonated β-cyclodextrin macrocycle.
ΙΕ Ο Β ο Γ ο ο [0023] As used herein ascorbic acid comprises neutral ascorbic acid and the anionic derivative ascorbate.
[0024] Desirably, the sensor of the present invention comprises a conducting substrate. As will be appreciated by a person skilled in the art the conducting substrate may comprise a metal selected from the group consisting of Pt, Ag, Au, Ru, Rh, Pd,
Re, Os, Ir, Ti, Indium tin oxide (ITO) coated glass and combinations thereof. Further still, the conducting substrate may comprise a non-metallic conductor such as carbon fibres, graphite, glassy carbon, diamond, carbon paste and pyrolithic carbon electrodes, or boron doped diamond. Desirably, the conducting substrate comprises Au.
[0025] Preferably, the conducting polymer is a biocompatible conducting polymer. As used herein the term biocompatible is a reference to materials that are non-toxic to biological tissues.
[0026] The conducting polymer of the sensor of the present invention may be selected from the group consisting of polythiophene materials, polypyrrole materials and combinations thereof. Desirably, the conducting polymer comprises a polythiophene material. Suitably, the conducting polymer comprises PEDOT [polyethylenedioxythiophene].
[0027] The electrode and sensor of the present invention provide for detecting serotonin in solution. As used herein the term solution comprises bodily fluids such as plasma, blood, extra-cellular fluid, etc. having serotonin dissolved therein.
[0028] Advantageously, the electrodes utilised in detecting serotonin levels have the potential to be miniaturised and conveniently placed in the living organism to give invivo data at the sub-second timescale.
[0029] Advantageously, the electrode and sensor of the present invention provide for real-time measurement of serotonin, both in-vivo and in-vitro. Further still, the electrode and sensor of the present invention for detecting serotonin has the potential for in-situ monitoring.
[0030] Potential applications of the electrode and sensor of the present invention include the evaluation of test compounds on serotonin concentrations in the brain, and the resulting neurological response.
[0031] The relative simplicity with which these materials can be prepared, coupled with the excellent selectivity, high biocompatibility and ease of preparation shows that these novel materials have real potential in the sensing of Serotonin and are a significant improvement on the existing technologies. The materials utilised in the electrode are
ΙΕ Ο 8 Ο ί, Ο Ο highly biocompatible (PEDOT is used in tissue engineering applications and cyclodextrins are used In drug delivery) and easy to prepare (10-min preparation time)
Brief Description of the Drawings [0032] Additional features and advantages of the present invention are described in, and will be apparent from, the detailed description of the invention and from the drawings in which:
[0033] Figure 1 illustrates electropolymerisation of PEDOT/cydodextrin film at a Gold electrode according to the present invention. Potential cycled from -0 5 to +1 06 V vs SCE [0034] Figure 2 illustrates the cyclic voltammetric response of the PEDOT/sulfonated β-CD film on a gold electrode according to the present invention to 5x10'5 Μ 5-HT and a mixture of 5x1 O'5 M 5-HT & 5x104 Μ AA.
[0035] Figure 3 depicts the cyclic voltammetric response of the PEDOT/sulfonated βCD film on a gold electrode according to the present invention to 5x105 M 5-HT & DA, and a mixture of 5x10‘6 M 5-HT, DA & AA.
[0036] Figure 4 depicts the cyclic voltammetric response of the PEDOT/sulfonated βCD film on a gold electrode according to the present invention to a mixture of 5-HT, AA, DA, EP and norEP
Detailed Description of the Invention
Preparation of the Electrode [0037] The poor solubility of the 3,4-ethylene dioxythiophene (EDOT) monomer in aqueous solution, has led to the electropolymerisation of this monomer being predominantly performed in organic media.1,2 Surfactants, such as sodium dodecyl sulphate (SDS), have been reported to improve the solubility of EDOT in aqueous and organic media? In general, it has been communicated that a critical micellar concentration (cmc) of surfactant is required in solution if polymerisation of EDOT is to occur Cyclodextrins have been used in place of surfactants?·5 owing to the ability of cyclodextrins to form a host guest interaction with EDOT, thus increasing the solubility of the EDOT monomer in water In the example disclosed herein, sulfonated βcyclodextrin (β-CD) was utilised as the dopant anion necessary for film formation to occur.
[0038] The films were electropolymerised onto gold electrodes from an aqueous solution of 0.1 M ethylenedioxythiophene and 0.01 M sulfonated β-cyclodextrin, sodium
IE 0 8 0 9 0 0 salt Polymerisation was carried out by cycling the potential between -0.5 and 1.06 V/SCE at a scan rate of 50 mV s'1 for a total of three cycles.
[0039] The PEDOT/sulfonated β-cyclodextrin film properties vary depending on:
a) the EDOT;sulfonated β-CD solution concentrations (and ratio); and
b) the polymerisation technique utilised - when cyclic voltammetry is utilised the following parameters can be modified to vary the PEDOT/sulfonated βcyclodextrin film properties;
i) the upper (anodic) potential of the voltammetric sweep used when fabricating the polymer film. This upper potential is important for system optimisation, and ii) the sweep rate.
[0040] The conditions resulting in optimal serotonin sensing comprise:
• a polymerisation solution of 0.1M EDOT:0.01M sulfonated β-CD; this 10:1 ratio is important;
• cyclic voltammetry (CV) is important to ensure that a homogeneous thin film is formed. Films grown using this technique exhibit enhanced serotonin signals when compared to potentiostatic growth films;
• sweeping from -0.5 to +1.06 V vs SCE at a scan rate of 50 mV s’; and • three electropolymerisation cycles to form a thin but a homogeneous film.
[0041] All scans were completed on a Solartron 1285 potentiostat. The data provided herein and in the figures were obtained using cyclic voltammetry.
[0042] For example, in Figure 1 we see a cyclic voltammagram of three electropolymerisation cycles of a solution of 0.1M EDOT:0.01M sulfonated β-CD, Irreversible oxidation, i.e. electropolymerisation of the monomer occurs at approximately 0.8V and leads to film formation (101). No peak in the reverse sweep direction indicates that this is essentially an irreversible process.
Serotonin (5-HT) Detection
Detection at the PEDOT/CD film:
[0043] The cyclic voltammetric response of the PEDOT/sulfonated β-CD film on a gold electrode to 5x1 O'5 M 5-HT (trace 201) and a mixture of 5x10'5 M 5-HT & 5x10 Μ AA (trace 202) is shown in shown in Figure 2. The main 5-HT oxidation peak is observed at -0 48V in the 5-HT only trace 201. In trace 202 the 5-HT peak is measured in the presence of AA. In the presence of AA the 5-HT peak is shifted slightly to *0.5V.
Thus, the electrode array of the present invention comprising the PEDOT/sulfonated βCD film can selectively detect 5-HT in the presence of AA,
Interference of Dopamine (DA) with the Serotonin (5-HT) oxidation signal:
[0044] As dopaminergic and serotoninergic neurons are active within close proximity in the animal/human brain desirably the electrode array of the present invention should be capable of detecting 5-HT in the presence of DA. Figure 3 shows the cyclic voltammetric response of the PEDOT/sulfonated β-CD film on a gold electrode according to the present invention to 5x105 M 5-HT & DA (lower trace 301), and a mixture of 5x1O'5 M 5-HT. DA & AA (upper trace 302). In 301, notwithstanding an overlap between the two peaks, we observe separate signals for DA 303 and 5-HT 304 The oxidation peaks are at -0.41V and -0 48V respectively. Trace 302 in the presence of AA, DA and 5-HT illustrates separate discernable peaks for AA 305, DA 306 and 5-HT 307.
[0045] Gratifyingly, the elecfrode comprising the PEDOT/sulfonated β-CD film according to the present invention was capable of selectively detecting all three species as independent peaks.
Selective Detection of Serotonin in the presence of Ascorbic Acid (AA), Dopamine (DA), Epinephrine (EP) and Norepinephrine (norEP):
[0046] Similarly, selective detection of 5-HT in the presence of AA, DA, EP and norEP was evaluated. Figure 4 shows the cyclic vottammetric response of the PEDOT/sulfonated β-CD film on a gold electrode according to the present invention to a mixture of 1.67x10’5 M 5-HT, 2x10’4 AA, 2x10’5 DA, 1x10 s EP and 6.67x10 6 norEP. The signals labelled 401 at -0.035V, -0.15V & -0.5V correspond to 5-HT. Signal 402 at -0.2V is from ascorbic acid, and signal 403 at -0.42V is a mixture of DA, EP and norEP.
[0047] Figure 4 clearly illustrates that the gold electrode comprising the PEDOT/sulfonated β-CD film according to the present invention is capable of selectively detecting 5-HT in the presence of AA, DA, EP and norEP.
[004&] The words “comprises/comprising and the words “having/including when used herein with reference to the present invention are used to specify the presence of stated features, integers, steps or components but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
ΙΕ Ο 8 o S G ο [0049] It is appreciated that certain features ofthe invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination
References
1. V. Noel, H. Randriamahazaka, C, Chevrot, J. Electroana!. Chem., 542 (2003) 33.
2. J Bobacka, A. Lewenstam, A. Ivaska, J. Eiectroanal. Chem. 489 (2000) 17.
3. N. Sakmeche, J. J. Aaron, M. Fall, S Aeiyach. M Jouini, J. C. Lacroix, P. C Lacaze, Chem. Commun., (1996), 2723.
4. C. Lagrost, J. C. Lacroix, S. Aeiyach, M. Jouini, K. I. Chane-Ching, P C Lacaze, Chem. Commun, (1998), 489.
V. S. Vasantha, K. L. N. Phani, J. Eiectroanal. Chem., 520 (2002), 79.
ΙΕ ο 8 Ο 3 ο ο
Claims (25)
1. An electrode for detecting serotonin comprising: (i) a conducting or semi-conducting substrate; and (ii) a polymer material on said substrate, wherein said polymer comprises a conducting polymer doped with a cyclodextrin macrocycle.
2. An electrode according to Claim 1 wherein the substrate comprises a conducting substrate.
3. An electrode according to Claim 1 or 2 wherein the conducting substrate comprises Au.
4. An electrode according to any preceding Claim wherein the conducting polymer is selected from the group consisting of polythiophenes, polypyrroles and combinations thereof.
5. An electrode according to Claim 4 wherein the conducting polymer comprises a polythiophene.
6. An electrode according to Claim 5, wherein the conducting polymer comprises polyethylenedioxythiophene.
7. An electrode according to any preceding Claim wherein the cyclodextrin comprises an anionic cyclodextrin.
8. An electrode according to Claim 7, wherein the anionic cyclodextrin comprises an amonic a-cyclodextrin, β-cyclodextrin, γ-cyclodextrin and combinations thereof
9. An electrode according to Claim 7 or 8, wherein the anionic cyclodextrin comprises an anionic β-cyclodextrin.
10. An electrode according to Claim 9 wherein the anionic β-cyclodextrin comprises a sulfonated^-cyclodextrin. IE Ο 8 Ο 9 Ο Ο
11. A sensor for selective detection of serotonin in the presence of dopamine, epinephrine, norepinephrine, ascorbic acid and combinations thereof comprising: an electrode comprising: (i) a conducting or semi-conducting substrate; and (ii) a polymer material on said substrate, wherein said polymer comprises a conducting polymer doped with a sulfonated β-cyclodextrin macrocycle
12. A sensor according to Claim 11 comprising a conducting substrate
13. A sensor according to Claim 12 wherein the conducting substrate comprises Au.
14. A sensor according to any preceding Claim wherein the conducting polymer is selected from the group consisting of polythiophene materials, polypyrrole materials and combinations thereof.
15. A sensor according to Claim 14 wherein the conducting polymer comprises a polythiophene material. 15 A sensor according to Claim 15, wherein the conducting polymer comprises polyethy lened ioxythiophene.
16. 17. A method of preparing an electrode for detecting serotonin comprising: (i) providing a conducting or semi-conducting substrate; (ii) providing an aqueous solution of a monomeric precursor to a conducting polymer and an anionic cyclodextrin; (iii) contacting said substrate and said aqueous solution; and (iv) applying an electrical potential to provide an anionic cyclodextrin doped conducting polymer film on said substrate.
17. 18 A method according to Claim 17 wherein the monomeric precursor to a conducting polymer comprises a monomeric precursor to a polythiophene, a monomeric precursor to a poly pyrrole and combinations thereof
18. 19. A method according to Claim 18 wherein the monomeric precursor to a conducting polymer comprises a monomeric precursor to a polythiophene. IE
19. 20. A method according to Claims 17 Io 19 wherein the monomeric precursor to a conducting polymer comprises ethylenedioxythiophene.
20. 21. A method according to any preceding Claim comprising providing a conducting substrate
21. 22. A method according to Claim 21 wherein the conducting substrate comprises Au.
22. 23 A method according to any preceding Claim wherein the anionic cyclodextrin comprises an anionic a-cyciodextrin, β-cyclodextrin, γ-cyclodextrin and combinations thereof.
23. 24 A method according to Claim 23 wherein the anionic cyclodextrin comprises an anionic β-cyclodextrin.
24.
25. A method according to Claim 24 wherein the anionic β-cyclodextrin comprises a sulfonated^-cyclodextrin.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IES20080900 IES20080900A2 (en) | 2008-11-10 | 2008-11-10 | Chemical messenger sensor |
| PCT/EP2009/064942 WO2010052342A2 (en) | 2008-11-10 | 2009-11-10 | Chemical messenger sensor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IES20080900 IES20080900A2 (en) | 2008-11-10 | 2008-11-10 | Chemical messenger sensor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IES20080900A2 true IES20080900A2 (en) | 2010-05-12 |
Family
ID=42107372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IES20080900 IES20080900A2 (en) | 2008-11-10 | 2008-11-10 | Chemical messenger sensor |
Country Status (2)
| Country | Link |
|---|---|
| IE (1) | IES20080900A2 (en) |
| WO (1) | WO2010052342A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170027184A (en) * | 2015-09-01 | 2017-03-09 | (주) 원메디칼 | Allergen detection apparatus according to an electrochemical detection method |
| CN106353376A (en) * | 2016-08-30 | 2017-01-25 | 南京师范大学 | Beta-adrenal agonists residue detection electrochemical sensor and detection methods thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2706067B1 (en) * | 1993-06-03 | 1995-07-07 | Commissariat Energie Atomique | Conductive polymer doped with a sulfonated cyclodextrin salt and device for capturing and / or delivering an active substance, comprising this polymer. |
| US6582583B1 (en) * | 1998-11-30 | 2003-06-24 | The United States Of America As Represented By The Department Of Health And Human Services | Amperometric biomimetic enzyme sensors based on modified cyclodextrin as electrocatalysts |
| AT408662B (en) * | 2000-05-16 | 2002-02-25 | Hoffmann La Roche | Creatinine SENSOR |
| WO2006127023A2 (en) * | 2004-08-24 | 2006-11-30 | University Of South Florida | Epoxy enhanced polymer membrane to increase durability of biosensors |
-
2008
- 2008-11-10 IE IES20080900 patent/IES20080900A2/en not_active Application Discontinuation
-
2009
- 2009-11-10 WO PCT/EP2009/064942 patent/WO2010052342A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010052342A3 (en) | 2010-07-15 |
| WO2010052342A2 (en) | 2010-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GhavamiNejad et al. | A conductive hydrogel microneedle‐based assay integrating PEDOT: PSS and Ag‐Pt nanoparticles for real‐time, enzyme‐less, and electrochemical sensing of glucose | |
| Thakur et al. | Ultrasensitive electrochemical biosensors for dopamine and cholesterol: recent advances, challenges and strategies | |
| Peltola et al. | Electrochemical fouling of dopamine and recovery of carbon electrodes | |
| Xiao et al. | In vivo analysis with electrochemical sensors and biosensors | |
| Wang et al. | Au-nanoclusters incorporated 3-amino-5-mercapto-1, 2, 4-triazole film modified electrode for the simultaneous determination of ascorbic acid, dopamine, uric acid and nitrite | |
| Feng et al. | Low-fouling nanoporous conductive polymer-coated microelectrode for in vivo monitoring of dopamine in the rat brain | |
| Yang et al. | High-performance conducting polymer nanofiber biosensors for detection of biomolecules | |
| Uang et al. | Fabrication of glucose oxidase/polypyrrole biosensor by galvanostatic method in various pH aqueous solutions | |
| Jiang et al. | Novel modifications to carbon-based electrodes to improve the electrochemical detection of dopamine | |
| Xiang et al. | Vertically aligned carbon nanotube-sheathed carbon fibers as pristine microelectrodes for selective monitoring of ascorbate in vivo | |
| Zhang et al. | Carbon nanotube-modified carbon fiber microelectrodes for in vivo voltammetric measurement of ascorbic acid in rat brain | |
| Wang et al. | Enhanced catalytic and dopamine sensing properties of electrochemically reduced conducting polymer nanocomposite doped with pure graphene oxide | |
| Kan et al. | Imprinted electrochemical sensor for dopamine recognition and determination based on a carbon nanotube/polypyrrole film | |
| Wooten et al. | On the direct electron transfer, sensing, and enzyme activity in the glucose oxidase/carbon nanotubes system | |
| Patel et al. | Comparison and reappraisal of carbon electrodes for the voltammetric detection of dopamine | |
| Wang et al. | Improvement of the biocompatibility and potential stability of chronically implanted electrodes incorporating coating cell membranes | |
| Fu et al. | A solid-state electrochemical sensing platform based on a supramolecular hydrogel | |
| Ates et al. | Carbon fiber microelectrodes electrocoated with polycarbazole and poly (carbazole-co-p-tolylsulfonyl pyrrole) films for the detection of dopamine in presence of ascorbic acid | |
| Fusco et al. | Aqueous polythiophene electrosynthesis: A new route to an efficient electrode coupling of PQQ-dependent glucose dehydrogenase for sensing and bioenergetic applications | |
| Saleh et al. | Bioelectronic interfaces of organic electrochemical transistors | |
| Sriprasertsuk et al. | Polypyrrole-coated carbon fibre electrodes for paracetamol and clozapine drug sensing | |
| Fabregat et al. | Detection of dopamine using chemically synthesized multilayered hollow microspheres | |
| Hernández‐Jiménez et al. | Voltammetric determination of metronidazole using a sensor based on electropolymerization of α‐cyclodextrin over a carbon paste electrode | |
| Senel et al. | Enhanced electrochemical sensing performance by in situ electrocopolymerization of pyrrole and thiophene-grafted chitosan | |
| US20100116655A1 (en) | Chemical messenger sensor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FJ9A | Application deemed to be withdrawn section 31(3) |